This study tests if adding new drugs, monalizumab or oleclumab, to durvalumab and radiation therapy is safe for treating certain lung cancers. Durvalumab and the new drugs are types of monoclonal antibodies, which help the immune system fight cancer by targeting specific proteins on cancer cells. The study uses radiation therapy in two ways: ACRT (Accelerated Hypofractionated Radiation Therapy), which gives higher doses in a shorter time, and conventional, which is more spread out. Patients are divided into groups to test different combinations of these treatments. Safety and effectiveness are checked with tests like MRIs and CT scans, and blood samples are collected.

• Participation involves regular check-ups and scans for up to two years after treatment.
• The study includes a combination of drugs given through IV (intravenous) every few weeks.
• There are some risks and eligibility requirements, like specific health conditions and prior treatments.